Taiwan · Delayed Price · Currency is TWD RBC Bioscience Statistics
Total Valuation
RBC Bioscience has a market cap or net worth of TWD 309.74 million. The enterprise value is 655.41 million.
| Market Cap | 309.74M |
| Enterprise Value | 655.41M |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | Sep 2, 2026 |
Share Statistics
RBC Bioscience has 14.27 million shares outstanding. The number of shares has increased by 0.14% in one year.
| Current Share Class | 14.27M |
| Shares Outstanding | 14.27M |
| Shares Change (YoY) | +0.14% |
| Shares Change (QoQ) | -0.41% |
| Owned by Insiders (%) | 29.02% |
| Owned by Institutions (%) | n/a |
| Float | 6.78M |
Valuation Ratios
The trailing PE ratio is 14.76.
| PE Ratio | 14.76 |
| Forward PE | n/a |
| PS Ratio | 1.40 |
| PB Ratio | 1.19 |
| P/TBV Ratio | 1.27 |
| P/FCF Ratio | 7.38 |
| P/OCF Ratio | 7.48 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.51, with an EV/FCF ratio of 15.63.
| EV / Earnings | 31.12 |
| EV / Sales | 2.97 |
| EV / EBITDA | 15.51 |
| EV / EBIT | 24.49 |
| EV / FCF | 15.63 |
Financial Position
The company has a current ratio of 1.08, with a Debt / Equity ratio of 1.50.
| Current Ratio | 1.08 |
| Quick Ratio | 0.61 |
| Debt / Equity | 1.50 |
| Debt / EBITDA | 9.20 |
| Debt / FCF | 9.27 |
| Interest Coverage | 2.92 |
Financial Efficiency
Return on equity (ROE) is 8.09% and return on invested capital (ROIC) is 3.52%.
| Return on Equity (ROE) | 8.09% |
| Return on Assets (ROA) | 2.26% |
| Return on Invested Capital (ROIC) | 3.52% |
| Return on Capital Employed (ROCE) | 4.44% |
| Weighted Average Cost of Capital (WACC) | 4.04% |
| Revenue Per Employee | 4.41M |
| Profits Per Employee | 421,160 |
| Employee Count | 50 |
| Asset Turnover | 0.30 |
| Inventory Turnover | 2.41 |
Taxes
In the past 12 months, RBC Bioscience has paid 5.40 million in taxes.
| Income Tax | 5.40M |
| Effective Tax Rate | 20.39% |
Stock Price Statistics
The stock price has increased by +15.76% in the last 52 weeks. The beta is 0.46, so RBC Bioscience's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | +15.76% |
| 50-Day Moving Average | 21.37 |
| 200-Day Moving Average | 18.59 |
| Relative Strength Index (RSI) | 47.69 |
| Average Volume (20 Days) | 85,633 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, RBC Bioscience had revenue of TWD 220.60 million and earned 21.06 million in profits. Earnings per share was 1.47.
| Revenue | 220.60M |
| Gross Profit | 101.60M |
| Operating Income | 26.77M |
| Pretax Income | 26.45M |
| Net Income | 21.06M |
| EBITDA | 41.04M |
| EBIT | 26.77M |
| Earnings Per Share (EPS) | 1.47 |
Balance Sheet
The company has 43.18 million in cash and 388.85 million in debt, with a net cash position of -345.67 million or -24.22 per share.
| Cash & Cash Equivalents | 43.18M |
| Total Debt | 388.85M |
| Net Cash | -345.67M |
| Net Cash Per Share | -24.22 |
| Equity (Book Value) | 260.09M |
| Book Value Per Share | 18.22 |
| Working Capital | 10.34M |
Cash Flow
In the last 12 months, operating cash flow was 41.40 million and capital expenditures 543,000, giving a free cash flow of 41.95 million.
| Operating Cash Flow | 41.40M |
| Capital Expenditures | 543,000 |
| Depreciation & Amortization | 14.27M |
| Net Borrowing | -48.44M |
| Free Cash Flow | 41.95M |
| FCF Per Share | 2.94 |
Margins
Gross margin is 46.05%, with operating and profit margins of 12.13% and 9.55%.
| Gross Margin | 46.05% |
| Operating Margin | 12.13% |
| Pretax Margin | 11.99% |
| Profit Margin | 9.55% |
| EBITDA Margin | 18.60% |
| EBIT Margin | 12.13% |
| FCF Margin | 19.01% |
Dividends & Yields
This stock pays an annual dividend of 3.53, which amounts to a dividend yield of 14.98%.
| Dividend Per Share | 3.53 |
| Dividend Yield | 14.98% |
| Dividend Growth (YoY) | 1,478.20% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 20.33% |
| Buyback Yield | -0.14% |
| Shareholder Yield | 14.83% |
| Earnings Yield | 6.80% |
| FCF Yield | 13.54% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 11, 2025. It was a forward split with a ratio of 1.1.
| Last Split Date | Aug 11, 2025 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
RBC Bioscience has an Altman Z-Score of 0.9 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.9 |
| Piotroski F-Score | 6 |